ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
PERCHERON FPO
0.004
0.000
-11.11%
成交量:
- -
成交額:
- -
市值:
728.97萬
市盈率:
-0.98
高:
0.004
開:
0.004
低:
0.004
收:
0.005
52周最高:
0.011
52周最低:
0.002
股本:
18.22億
流通股本:
8.17億
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
每股收益(TTM):
-0.004
每股收益(LYR):
-0.004
淨資產收益率:
-54.66%
總資產收益率:
-28.90%
市淨率:
0.97
市盈率(LYR):
-0.98
資料載入中...
總覽
公司
新聞
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞
Percheron Therapeutics尋求停牌,擬融資以資助與範德比爾特健康的合作研究
美股速递
·
08/28
Percheron Therapeutics Ltd——範德比爾特健康中心將開展Hmbd-002治療急性髓系白血病的臨床試驗
美股速递
·
08/28
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/PER.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PER.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","market":"AU","secType":"STK","nameCN":"PERCHERON FPO","latestPrice":0.004,"timestamp":1789107120000,"preClose":0.0045,"halted":0,"volume":0,"delay":0,"changeRate":-0.11111111111111102,"nameEN":"PERCHERON FPO","floatShares":816628906,"shares":1822415536,"eps":-0.0041,"marketStatus":"休市中","change":-0.0005,"latestTime":"09-11 16:12:00 AEST","open":0.004,"high":0.004,"low":0.004,"amount":0,"amplitude":0,"askPrice":0.005,"askSize":6161461,"bidPrice":0.004,"bidSize":19789750,"shortable":3,"etf":0,"ttmEps":-0.0041,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.0045,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PER.AU","preClose":0.006,"auctionPrice":0.004,"auctionVolume":100000,"auction":3,"marketStatus":"盘后竞价","timestamp":1788847725650}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","floatShares":816628906,"roa":"-28.90%","roe":"-54.66%","lyrEps":-0.0041,"shares":1822415536,"dividePrice":0,"high":0.004,"amplitude":0,"preClose":0.0045,"low":0.004,"week52Low":0.002,"pbRate":"0.97","psRate":"8.64","week52High":0.011,"institutionHeld":0,"latestPrice":0.004,"committee":0.52515,"eps":-0.0041,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.0041,"open":0.004,"prevYearClose":0.009,"prevWeekClose":0.005,"prevMonthClose":0.005,"prevQuarterClose":0.003,"fiveDayClose":0.005,"twentyDayClose":0.005,"sixtyDayClose":0.005},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PER.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PER.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PER.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1139987884","title":"Percheron Therapeutics尋求停牌,擬融資以資助與範德比爾特健康的合作研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1139987884","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139987884?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 07:03","pubTimestamp":1787871792,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics宣布,已申请股票交易停牌,此举旨在推进一项资本筹集计划,为与范德比尔特健康(Vanderbilt Health)合作开展的研究项目提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","PER.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151077858","title":"Percheron Therapeutics Ltd——範德比爾特健康中心將開展Hmbd-002治療急性髓系白血病的臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1151077858","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151077858?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 06:12","pubTimestamp":1787868773,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics Ltd宣布,范德比尔特健康中心将主导一项针对Hmbd-002的临床试验,该试验聚焦于急性髓系白血病的治疗。此次与范德比尔特健康中心的携手,有望为急性髓系白血病患者带来新的治疗选择。临床试验的具体细节尚未完全披露,但此举无疑凸显了Percheron Therapeutics在肿瘤学领域的持续深耕。急性髓系白血病是一种进展迅速的血癌,现有治疗方案有限,且复发风险较高。Percheron Therapeutics此番布局,正是瞄准了这一未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","PER.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PER.AU\",params:#limit:6,delay:true,,,undefined,":[]}}